Positron emission tomography study of changes in [11C]AZ14132516 uptake following administration of AZD7798 to patients with Crohn’s disease.

Trial Identifier:	D9690C00007
Sponsor:	AstraZeneca
Start Date:	August 2024
Primary Completion Date:	February 2026
Study Completion Date:	February 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
Sweden	Stockholm, Sweden, 141 86

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.